Your browser doesn't support javascript.
loading
Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.
Culjkovic-Kraljacic, Biljana; Fernando, Tharu M; Marullo, Rossella; Calvo-Vidal, Nieves; Verma, Akanksha; Yang, ShaoNing; Tabbò, Fabrizio; Gaudiano, Marcello; Zahreddine, Hiba; Goldstein, Rebecca L; Patel, Jayeshkumar; Taldone, Tony; Chiosis, Gabriela; Ladetto, Marco; Ghione, Paola; Machiorlatti, Rodolfo; Elemento, Olivier; Inghirami, Giorgio; Melnick, Ari; Borden, Katherine L B; Cerchietti, Leandro.
Afiliación
  • Culjkovic-Kraljacic B; Institute for Research in Immunology and Cancer and Department of Pathology and Cell Biology, Université de Montréal, Montréal, QC, Canada;
  • Fernando TM; Hematology and Oncology Division.
  • Marullo R; Hematology and Oncology Division.
  • Calvo-Vidal N; Hematology and Oncology Division.
  • Verma A; Department of Physiology and Biophysics, Institute for Computational Biomedicine, and.
  • Yang S; Hematology and Oncology Division.
  • Tabbò F; Pathology and Laboratory Medicine Department, Weill Cornell Medical College, Cornell University, New York, NY; Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Turin, Turin, Italy;
  • Gaudiano M; Pathology and Laboratory Medicine Department, Weill Cornell Medical College, Cornell University, New York, NY;
  • Zahreddine H; Institute for Research in Immunology and Cancer and Department of Pathology and Cell Biology, Université de Montréal, Montréal, QC, Canada;
  • Goldstein RL; Hematology and Oncology Division.
  • Patel J; Hematology and Oncology Division.
  • Taldone T; Department of Molecular Pharmacology and Chemistry, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY; and.
  • Chiosis G; Department of Molecular Pharmacology and Chemistry, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY; and.
  • Ladetto M; Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Turin, Turin, Italy; Division of Hematology, Department of Experimental Medicine and Oncology, University of Turin, Turin, Italy.
  • Ghione P; Division of Hematology, Department of Experimental Medicine and Oncology, University of Turin, Turin, Italy.
  • Machiorlatti R; Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Turin, Turin, Italy;
  • Elemento O; Department of Physiology and Biophysics, Institute for Computational Biomedicine, and.
  • Inghirami G; Pathology and Laboratory Medicine Department, Weill Cornell Medical College, Cornell University, New York, NY;
  • Melnick A; Hematology and Oncology Division.
  • Borden KL; Institute for Research in Immunology and Cancer and Department of Pathology and Cell Biology, Université de Montréal, Montréal, QC, Canada;
  • Cerchietti L; Hematology and Oncology Division.
Blood ; 127(7): 858-68, 2016 Feb 18.
Article en En | MEDLINE | ID: mdl-26603836
Aggressive double- and triple-hit (DH/TH) diffuse large B-cell lymphomas (DLBCLs) feature activation of Hsp90 stress pathways. Herein, we show that Hsp90 controls posttranscriptional dynamics of key messenger RNA (mRNA) species including those encoding BCL6, MYC, and BCL2. Using a proteomics approach, we found that Hsp90 binds to and maintains activity of eIF4E. eIF4E drives nuclear export and translation of BCL6, MYC, and BCL2 mRNA. eIF4E RNA-immunoprecipitation sequencing in DLBCL suggests that nuclear eIF4E controls an extended program that includes B-cell receptor signaling, cellular metabolism, and epigenetic regulation. Accordingly, eIF4E was required for survival of DLBCL including the most aggressive subtypes, DH/TH lymphomas. Indeed, eIF4E inhibition induces tumor regression in cell line and patient-derived tumorgrafts of TH-DLBCL, even in the presence of elevated Hsp90 activity. Targeting Hsp90 is typically limited by counterregulatory elevation of Hsp70B, which induces resistance to Hsp90 inhibitors. Surprisingly, we identify Hsp70 mRNA as an eIF4E target. In this way, eIF4E inhibition can overcome drug resistance to Hsp90 inhibitors. Accordingly, rational combinatorial inhibition of eIF4E and Hsp90 inhibitors resulted in cooperative antilymphoma activity in DH/TH DLBCL in vitro and in vivo.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: ARN Mensajero / ARN Neoplásico / Protocolos de Quimioterapia Combinada Antineoplásica / Núcleo Celular / Linfoma de Células B / Proteínas de Neoplasias Límite: Humans Idioma: En Revista: Blood Año: 2016 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: ARN Mensajero / ARN Neoplásico / Protocolos de Quimioterapia Combinada Antineoplásica / Núcleo Celular / Linfoma de Células B / Proteínas de Neoplasias Límite: Humans Idioma: En Revista: Blood Año: 2016 Tipo del documento: Article